Confo Therapeutics’ Technology as a Superior Platform for Fragment-Based Drug Discovery on Difficult to Drug GPCRs
Time: 4:30 pm
day: Conference Day One
Details:
- What is the most optimum workflow for performing fragment-based drug discovery to identify selective and ligand efficient small molecules?
- Is there utility in the ultra-large scale screening of drug-like compounds or should we be more selective?
